Everything you need, all in one place

 

This is your Novartis hub, newly designed to provide you, the healthcare professional, with everything you need to support you and your patients. On NovartisPro Ireland you will find all of the existing content with the addition, in some instances, of new and updated content.

NovartisPro Ireland contains the latest product information, resources and training materials, alongside events, webinars, formulary and service support. Everything you need to help you deliver excellent care for your patients.

 

Medical information:

 

+353 1 260 1255

[email protected]

logo-kisqali-product-card
Oncology
KISQALI® (ribociclib)
Prescribing information
Kesimpta logo.
Neuroscience
KESIMPTA®▼(ofatumumab)
Prescribing information

September 2025 | IE11499091

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported to HPRA Pharmacovigilance at www.hpra.ie. Adverse events can also be reported to Novartis preferably at www.novartis.com/report, by emailing [email protected] or by calling (01) 2080 612.